Jason Luke MD, FACP

Dr. Jason J. Luke Luke is one of the foremost international investigators in the realm of immuno-oncology, having led clinical trials of immunotherapies including but not limited to anti-PD1/L1, CTLA4, many secondary checkpoints, bispecific approaches (checkpoint, CD3 and cytokine), metabolism modifiers (IDO, A2Ar/CD73/CD39 and arginase), innate agonists of STING, TLRs and oncolytic virus as well as solid tumor cellular therapies (TCRs and CART).

In melanoma, Dr. Luke has designed and led two practice-changing trials determining the role of anti-PD1 + CTLA4 after initial anti-PD1 failure (compendium listed in the NCCN) and altering the landscape of melanoma oncology practice across dermatology, surgery, and medical oncology via the establishment of modern adjuvant therapy with anti-PD1 for node-negative stage IIB/C disease (leading to FDA/EMA approval). Dr. Luke has been a major contributor to the investigation of radiation and the microbiome in relation to cancer immunotherapy.

Dr. Luke’s major translational research focus leverages large-scale informatics to advance cancer immunotherapy. Dr. Luke has ongoing NIH funding for his translational research laboratory which focuses on tumor-intrinsic mechanisms of immune exclusion and designing next-generation immunotherapy approaches to overcome them.